Biogen to start shipping Alzheimer’s drug in about two weeks

Published by

(Reuters) -Biogen Inc said on Tuesday it expects to begin shipping its newly approved Alzheimer’s drug Aduhelm in about two weeks and has prepared more than 900 healthcare centers for the intravenous infusion treatment. The U.S. Food and Drug Administration on Monday approved Aduhelm as the first treatment to target a likely underlying cause of Alzheimer’s disease, sticky deposits of a protein called amyloid-beta. Biogen Chief Executive Officer Michel Vounatsos said on a call with analysts that the sites include clinical trial centers with currently confirmed amyloid-beta positive patients, as…

Read More

Share this Story
Load More Related Articles
Load More In US News

Facebook Comments

Check Also

Brazil environment minister quits; faces illegal logging probe

Published by Reuters By Jake Spring and Maria ...